[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643944":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":20,"locations":29,"responsibleParty":42,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Istanbul University - Cerrahpasa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with Group 1 Pulmonary Arterial Hypertension",null,"Participants are adult patients with established Group 1 pulmonary arterial hypertension (PAH) undergoing follow-up at a specialized pulmonary hypertension center.",[13,17],{"name":14,"affiliation":15,"role":16},"Aybüke Geylan, MD","Istanbul University Cerrahpasa Institute of Cardiology","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":15,"role":19},"Umit Yasar Sinan, Professor","STUDY_CHAIR",[21,25],{"name":14,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","+905061258579","aybukegeylan@gmail.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Barış Güven, MD","+905321137507","guvenbariss@gmail.com",[30],{"facility":15,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":10,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Istanbul","Turkey (Türkiye)",{"type":35,"coordinates":36},"Point",[37,38],28.94966,41.01384,{"lat":38,"lon":37},[41],{"name":14,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":16,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Neziha Aybuke Geylan, MD","Principal Investigator","100643944","multimodality-rv-phenotyping-for-risk-stratification-and-short-term-outcomes-in-group-1-pah-100643944",false,"NCT07667673","Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH","Multimodality Imaging-Based Right Ventricular Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 Pulmonary Arterial Hypertension: The MIRROR-PAH Study","MIRROR-PAH","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC\u002FERS guidelines\n* Followed at the study center with a diagnosis of PAH\n* Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval\n* Availability of analyzable clinical, imaging, and hemodynamic data\n* Willingness to participate in the study and provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH)\n* Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval\n* Incomplete clinical or imaging data preventing analysis\n* Unavailable follow-up data","ALL","18 Years",{"count":56,"type":57},50,"ESTIMATED","OBSERVATIONAL","The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening.\n\nAdult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.",[61,62,63],"Pulmonary Hypertension","Pulmonary Arterial Hypertension","Right Ventricular Function",[65,66,67,68,69],"pulmonary arterial hypertension","transthoracic echocardiography","cardiac magnetic resonance imaging","right heart catheterization","risk stratification","2026-06-19",{"date":72,"type":73},"2026-06-25","ACTUAL",{"date":75,"type":73},"2026-05-11",{"date":77,"type":57},"2027-05",{"name":5,"class":6},1]